Veracyte Stock Price, News & Analysis

Veracyte (NASDAQ: VCYT), a cancer diagnostics company, has announced its participation in two upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3rd at 5:40 p.m. ET, followed by a presentation at the Jefferies Global Healthcare Conference in New York on June 4th at 2:00 p.m. ET.

Live audio webcasts will be accessible through Veracyte's investor relations website, with replays available for 90 days following each presentation.

Veracyte (NASDAQ: VCYT) reported strong Q1 2025 financial results with total revenue reaching $114.5 million, up 18% year-over-year. The company achieved its eleventh consecutive quarter of 20%+ testing volume growth, primarily driven by Decipher and Afirma tests. Key highlights include:

- Testing revenue increased 19% to $107.3 million - Total testing volume grew 22% to 40,655 tests - Decipher revenue surged 33% to $66.6 million - Net income reached $7.0 million (6.2% of revenue) - Adjusted EBITDA was $24.7 million (21.6% of revenue)

The company maintained its 2025 testing revenue guidance of $470-480 million (12-15% growth) and raised adjusted EBITDA margin guidance to 22.5%. Additionally, Veracyte announced plans to discontinue funding its French subsidiary, with court proceedings expected to complete by end of 2025.

Veracyte (VCYT) has announced the expansion of its Decipher Prostate test to include patients with metastatic prostate cancer. The test, previously used only for localized disease, is now the only gene expression test covered by Medicare for treatment decisions across all prostate cancer risk levels.

The company will initially offer the Decipher Prostate Metastatic Genomic Classifier through an early access program at select clinical sites, with broader availability planned for June 2025. The test's clinical validity and utility have been validated through multiple Phase 3 clinical studies, demonstrating its ability to identify patients with more-aggressive tumor biology through high Decipher scores.

With approximately 30,000 metastatic prostate cancer cases diagnosed annually in the US (10% of all cases), this expansion addresses a significant medical need. The test aims to help clinicians determine which patients are likely to benefit from available treatments and which may avoid unnecessary toxic side effects.

Veracyte (VCYT) announced that 18 abstracts featuring its Decipher Prostate and Bladder Genomic Classifiers will be presented at the AUA 2025 conference in Las Vegas. The presentations will showcase new data from clinical trials and insights derived from the whole-transcriptome-based Decipher GRID research tool.

Key presentations include research on immune infiltration signatures in bladder cancer treatment response, transcriptomic examination of Grade Group 1 prostate cancer, and regional prostate cancer heterogeneity analysis. Dr. Vignesh Packiam will present findings on therapy response in high-risk non-muscle-invasive bladder cancer, while Dr. Nicole Handa will discuss molecular features of Grade Group 1 prostate cancer. Dr. Deepak Kapoor's research focuses on regional transcriptomic differences in prostate cancer patients.

Veracyte (VCYT) announced the inclusion of its Decipher Prostate Genomic Classifier data in the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program's new specialized database. This integration will allow researchers to analyze Decipher Prostate test results alongside real-world patient outcomes, cancer characteristics, treatment protocols, and demographics.

The SEER database linkage encompasses over 560,000 prostate cancer cases diagnosed from 2010 to 2018. The Decipher Prostate test has been available for radical prostatectomy specimens since 2013 and biopsy tissue since 2016. This collaboration reinforces Veracyte's commitment to building clinical evidence and advancing cancer research.

Veracyte (VCYT) has scheduled the release of its first quarter 2025 financial results after market close on Wednesday, May 7, 2025. The cancer diagnostics company will follow the release with a conference call and webcast at 4:30 p.m. Eastern Time, where management will discuss the financial performance and provide a business update.

Investors and interested parties can access the live webcast through the company's website, with a replay being made available afterward at the investor relations section.

Veracyte (VCYT) announced new data demonstrating superior accuracy of its whole-genome sequencing (WGS)-based minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer. The findings from the TOMBOLA trial, involving 100 patients, showed the platform detected cancer recurrence with higher specificity (88%) compared to ddPCR (62%), while maintaining equivalent negative predictive value (~96%).

The study revealed that Veracyte's MRD testing platform detected cancer recurrence 93 days earlier than standard imaging. The platform combines WGS and artificial intelligence to detect residual cancer in blood samples, requiring less blood and delivering faster results compared to traditional methods.

The company plans to launch its first MRD test for muscle-invasive bladder cancer in the first half of 2026. The platform establishes patient-specific genomic signatures by analyzing cancer mutations in tumor tissue and blood samples, enabling ongoing monitoring of tumor progression throughout treatment and follow-up care.

Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer. The company will also present independent performance data from a large, multicenter trial (TOMBOLA) supporting their minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer.

Dr. Philip Febbo, Veracyte's chief scientific officer and chief medical officer, highlighted how their whole-transcriptome approach enables partnerships with researchers to gain new insights into cancer biology. The company plans to launch an MRD test for muscle-invasive bladder cancer next year, utilizing their whole-genome approach.

Veracyte (VCYT) reported strong Q4 2024 financial results with total revenue increasing 21% to $118.6 million. Testing revenue grew 24% to $112.2 million, driven by impressive performance in Decipher (44% growth) and Afirma (4% growth) tests. Total test volume increased 22% to 41,271 tests.

For full-year 2024, total revenue rose 23% to $445.8 million, with testing revenue up 28% to $419.0 million. The company achieved net income of $24.1 million (5.4% of revenue) and adjusted EBITDA of $91.9 million (20.6% of revenue). Cash flow from operations was $75.1 million.

Looking ahead to 2025, Veracyte expects testing revenue between $470-480 million (12-15% growth) and adjusted EBITDA margin of approximately 21.6%. The company is evaluating its French subsidiary operations and considering potential divestiture or discontinuation of funding.